肠道菌群与非酒精性脂肪性肝炎发生发展的关系

常越; 李海

doi:10.3969/j.issn.1001-5256.2018.06.045

肠道菌群与非酒精性脂肪性肝炎发生发展的关系

DOI: 10.3969/j.issn.1001-5256.2018.06.045

常越,
李海

中国人民武装警察部队后勤学院附属医院肝胆胰脾科

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1235
- HTML全文浏览量: 9
- PDF下载量: 340
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-20
- 出版日期: 2018-06-20

The role of gut microbiota in the development and progression of nonalcoholic steatohepatitis

Chang Yue,
Li Hai

Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces

摘要

摘要: 目前非酒精性脂肪性肝炎(NASH)的发生机制仍不明确,经典的"二次打击"学说不能解释所有NASH的产生,对于肠道菌群改变与NASH发生、发展过程中的关系近些年越来越受重视。肠道菌群导致的能量代谢紊乱、脂多糖内毒素血症、内源性乙醇产生增加、胆汁酸代谢紊乱、胆碱代谢改变、免疫调控障碍等多个方面与NASH发生存在一定关系。综述了肠道菌群在NASH发生、发展过程中的作用。
- 肠道菌科 /
- 非酒精性脂肪性肝炎 /
- 病理过程 /
- 综述
Abstract: Currently, the pathogenesis of nonalcoholic steatohepatitis (NASH) remains unclear, while the theory of " two hits" is insufficient to explain the pathogenesis of NASH in all cases. More and more attention has been paid to the relationship between the change in gut microbiota and the development and progression of NASH in recent years. The energy metabolism disorder, lipopolysaccharide endotoxemia, increased endogenous ethanol production, bile acid metabolism disorder, altered choline metabolism, and immune dysfunction caused by gut microbiota are related to NASH. This article reviews the role of gut microbiota in the development and progression of nonalcoholic steatohepatitis.
- enterobacteriaceae /
- nonalcoholic steatohepatitis /
- pathologic processes /
- review

HTML全文

参考文献(38)

[1]ROTMAN Y, SANYAL AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J].Gut, 2017, 66 (1) :180-190

[2]DING YP, LI H, ZHANG W, et al.Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J].J Clin Hepatol, 2017, 33 (12) :2355-2360. (in Chinese) 丁玉平, 李海, 张文, 等.ALT升高的非酒精性脂肪性肝病的流行病学特征及其危险因素分析[J].临床肝胆病杂志, 2017, 33 (12) :2355-2360.

[3]BETRAPALLY NS, GILLEVET PM, BAJAJ JS.Gut microbiome and liver disease[J].Transl Res, 2017, 179:49-59.

[4]YI YR, ZENG Y, HE J, et al.Changes of intestinal flora in patients with non-alcoholic fatty liver disease and the effects of bifidobacterium triple viable capsules on intestinal flora, liver function, blood lipid and insulin resistance[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :87-92. (in Chinese) 易艳容, 曾亚, 何佳, 等.非酒精性脂肪性肝病患者肠道菌群变化及双歧杆菌三联活菌胶囊对肠道菌群、肝功能、血脂及胰岛素抵抗的影响[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :87-92.

[5]MRIDHA AR, WREE A, ROBERTSON AAB, et al.NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J].J Hepatol, 2017, 66 (5) :1037-1046.

[6]DAY CP, JAMES OF.Steatohepatitis:a tale of two"hits"?[J].Gastroenterology, 1998, 114 (4) :842-845.

[7]LEUNG JC, LOONG TC, WEI JL, et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology, 2017, 65 (1) :54-64.

[8]BELLANTI F, VILLANI R, TAMBORRA R, et al.Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression[J].Redox Biol, 2017, 15:86-96.

[9]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:The multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.

[10]SENDER R, FUCHS S, MILO R.Are we really vastly outnumbered?Revisiting the ratio of bacterial to host cells in humans[J].Cell, 2016, 164 (3) :337-340.

[11]ZHERNAKOVA A, KURILSHIKOV A, BONDER MJ, et al.Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J].Science, 2016, 352 (6285) :565-569.

[12]TANCA A, ABBONDIO M, PALOMBA A, et al.Potential and active functions in the gut microbiota of a healthy human cohort[J].Microbiome, 2017, 5 (1) :79.

[13]JUMPERTZ R, LE DS, TURNBAUGH PJ, et al.Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans[J].Am J Clin Nutr, 2011, 94 (1) :58-65.

[14] BOURSIER J, MUELLER O, BARRET M, et al.The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.

[15]LE RT, LLOPIS M, LEPAGE P, et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].Gut, 2013, 62 (12) :1787-1794.

[16]HENAOMEJIA J, ELINAV E, JIN C, et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature, 2012, 482 (7384) :179-185.

[17]XIE G, WANG X, LIU P, et al.Distinctly altered gut microbiota in the progression of liver disease[J].Oncotarget, 2016, 7 (15) :19355-19366.

[18]DRENICK EJ, FISLER J, JOHNSON D.Hepatic steatosis after intestinal bypass—prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition[J].Gastroenterology, 1982, 82 (3) :535-548.

[19]SHANAB AA, SCULLY P, CROSBIE O, et al.Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis:association with toll-like receptor 4 expression and plasma levels of interleukin 8[J].Dig Dis Sci, 2011, 56 (5) :1524-1534.

[20]ZENG QF, YANG GL, WANG CF.Application of probiotics in treatment of liver diseases[J].Chin J Immunol, 2016, 32 (11) :1711-1714. (in Chinese) 曾庆丰, 杨桂连, 王春凤.益生菌在肝脏疾病方面的应用[J].中国免疫学杂志, 2016, 32 (11) :1711-1714.

[21]BOURSIER J, MUELLER O, BARRET M, et al.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.

[22]BCKHED F, DING H, WANG T, et al.The gut microbiota as an environmental factor that regulates fat storage[J].Proc Natl Acad Sci U S A, 2004, 101 (44) :15718-15723.

[23]BOLOGNINI D, TOBIN AB, MILLIGAN G, et al.The pharmacology and function of receptors for short-chain fatty acids[J].Mol Pharmacol, 2016, 89 (3) :388-398.

[24]MATSUSHITA N, OSAKA T, HARUTA I, et al.Effect of lipopolysaccharide on the progression of non-alcoholic fatty liver disease in high caloric diet-fed mice[J].Scand J Immunol, 2016, 83 (2) :109-118.

[25]KIZILTAS S.Toll-like receptors in pathophysiology of liver diseases[J].World J Hepatol, 2016, 8 (32) :1354-1369.

[26]HUANG K, DU M, TAN X, et al.PARP1-mediated PPARαpoly (ADP-ribosyl) ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease[J].J Hepatol, 2017, 66 (5) :962-977.

[27]COPE K, RISBY T, DIEHL AM.Increased gastrointestinal ethanol production in obese mice:Implications for fatty liver disease pathogenesis[J].Gastroenterology, 2000, 119 (5) :1340-1347.

[28]NAIR S, COPE K, RISBY TH, et al.Obesity and female gender increase breath ethanol concentration:Potential implications for the pathogenesis of nonalcoholic steatohepatitis[J].Am J Gastroenterol, 2001, 96 (4) :1200-1204.

[29]HE CX, XU ZJ, FAN JG.Endogenous alcohol in non-alcoholic fatty liver disease[J].J Pract Hepatol, 2016, 19 (1) :109-112. (in Chinese) 何崇信, 徐正婕, 范建高.内生性乙醇与非酒精性脂肪性肝病研究进展[J].实用肝脏病杂志, 2016, 19 (1) :109-112.

[30]DUPARC T, PLOVIER H, MARRACHELLI VG, et al.Hepatocyte My D88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism[J].Gut, 2017, 66 (4) :620-632.

[31]JIAO N, BAKER SS, CHAPARODRIGUEZ A, et al.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J].Gut, 2017, 152 (5) :s1068.

[32]MOUZAKI M, WANG AY, BANDSMA R, et al.Bile acids and dysbiosis in non-alcoholic fatty liver disease[J].PLo S One, 2016, 11 (5) :e0151829.

[33]CHEN YM, LIU Y, ZHOU RF, et al.Associations of gut-floradependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults[J].Sci Rep, 2016, 8 (6) :19076.

[34]SPENCER MD, HAMP TJ, REID RW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J].Gastroenterology, 2011, 140 (3) :976-986.

[35]TANG YL, QIU DK, MA X.Interaction between Th17 cells and steatotic hepatocytes in nonalcoholic fatty liver disease[J].Chin Hepatol, 2010, 15 (2) :105-108. (in Chinese) 汤艳丽, 邱德凯, 马雄.Th17细胞与肝细胞脂肪变性的相互作用初探[J].肝脏, 2010, 15 (2) :105-108.

[36]SCHIRMER M, SMEEKENS SP, VLAMAKIS H, et al.Linking the human gut microbiome to inflammatory cytokine production capacity[J].Cell, 2016, 167 (4) :1125-1136.

[37]MA C, KESARWALA AH, EGGERT T, et al.NAFLD causes selective CD4+T lymphocyte loss and promotes hepatocarcinogenesis[J].Nature, 2016, 531 (7593) :253-257.

[38]SAYIN SI, WAHLSTRM A, FELIN J, et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist[J].Cell Metab, 2013, 17 (2) :225-235.

施引文献

资源附件(0)

访问统计